Merck’s Ifinatamab Deruxtecan Gains FDA Priority Review for Extensive-Stage SCLC
Merck’s investigational ADC, ifinatamab deruxtecan, earned FDA priority review for adults with previously treated extensive-stage small cell lung cancer after platinum-based chemotherapy. The designation grants a six-month review timeline, potentially accelerating market entry and bolstering late-stage oncology revenue prospects for Merck.
1. FDA Grants Priority Review
Merck’s ifinatamab deruxtecan received a priority review designation from the FDA for adult patients with extensive-stage small cell lung cancer who progressed after platinum-based chemotherapy. The priority review accelerates the standard review period to six months, signaling regulatory recognition of the unmet need in this hard-to-treat population.
2. Indication and Unmet Need
Extensive-stage SCLC patients often experience rapid relapse following first-line platinum regimens and face limited second-line options, with median survival under six months. Ifinatamab deruxtecan, an investigational antibody-drug conjugate, is designed to deliver targeted cytotoxic therapy and has shown encouraging early trial results.
3. Review Timeline and Next Steps
Under priority review, Merck has six months from the submission date to secure an FDA decision, potentially delivering approval before year-end. A favorable outcome would allow Merck to initiate final manufacturing scale-up, pricing discussions and commercial preparations promptly.
4. Commercial and Competitive Landscape
The second-line SCLC market is valued at over $1.5 billion annually, driven by high unmet need and limited alternatives. Ifinatamab deruxtecan could capture significant share from existing chemotherapies and emerging immunotherapies, enhancing Merck’s late-stage oncology portfolio and diversifying revenue streams.